Gitelman Syndrome Market Research Report – Global Forecast till 2027

Gitelman Syndrome Market Research Report, By Diagnosis (Urine Electrolytes Tests, Molecular Genetic Tests), By Treatment (Supplements, Medication), By End User (Hospitals & Clinics, Diagnostic Labs, Research Organization- Global Forecast till 2027

ID: MRFR/LS/3866-HCR | | Region: Global | 90 pages

Market Scenario:


Gitelman syndrome is a rare type of genetic disorder of the kidneys. It causes an imbalance of potassium, magnesium, and calcium ions within the patient’s body. Tetany, paresthesias, and fatigue are some of the common symptoms of Gitelman syndrome. The signs and symptoms of Gitelman syndrome usually appear in the late childhood or adolescence. According to the Genetics Home Reference (2018), it is estimated that the disease affects 1 in 40,000 people worldwide. Increasing global burden of chronic kidney diseases and growing biotechnology sector are the major drivers of the market. According to the International Society of Nephrology in 2015, the global mortality rate of chronic kidney diseases increased between 2005 and 2015 by 32%. This was estimated to account for 1.2 million deaths worldwide within the same year. Moreover, growing adolescent population and increased R&D expenses by the key players are estimated to boost the market growth during the projected period. According to the Child Trends, the number of the children under 18 years of age is projected to increase from 74.1 million to 78.2 million by 2040. However, factors such as stringent FDA approvals followed by the limited availability of the diagnostic and treatment options, low per capita healthcare expenditure, and lack of awareness are estimated to be the major restrains for the market growth during the forecasted period. 

The global Gitelman syndrome market is expected to grow at a CAGR of 7.6% during forecast period. 


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research And Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research And Consulting Service Providers 


Figure 1:- Global Gitelman Syndrome Market share, by Region Global Gitelman Syndrome Market


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Segmentation


The global Gitelman syndrome market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of the diagnosis, the market is segmented into urine electrolytes tests, molecular genetic tests, and others. The urine electrolytes tests are sub-segmented into sodium test, potassium test, chloride test, and others. The molecular genetic tests are sub-segmented into PCR (Polymerase Chain Reaction) hybridization and others.


On the basis of the treatment, the market is segmented into supplements, medication, and others. The supplements segment is sub-segmented into potassium supplement, magnesium supplement, and others. The medication segment is sub-segmented with diuretics and anti-inflammatory drugs (NSAIDS). The diuretics segment by medication is further segmented into spironolactone, amiloride, and others. The NSAIDS segment, by medication, is further segmented into ibuprofen, indomethacin, and others.


On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic labs, research organization, and others. 


Regional Analysis 


The Americas dominate the global Gitelman syndrome market owing to a well-developed healthcare sector, increasing the prevalence of chronic kidney diseases, and rising adolescent population. Additionally, changing lifestyle and presence of the developed economies like the U.S. and Canada within the region boost the market growth within the America region. 


Europe is the second largest Gitelman syndrome market and is followed by the Asia Pacific. Availability of funds for research, the huge patient population having chronic kidney diseases along with rising government support for research & development are driving the market growth. According to the British Kidney Patient Association in 2018, approximately 1 in every 8 people in the U.K are estimated to develop chronic kidney disease (CKD). 


The Asia Pacific is the fastest growing region in global the market due to the presence of a huge patient population and continuously developing economies like India and China, which have developing healthcare sector and rising healthcare expenditure. Moreover, growing biotechnology sector is boosting the market growth within the region. According to the Indian Brand Equity Foundation in 2017, the Indian biotechnology sector holds approximately 2.0% of the total biotechnology sector and is estimated to be a USD 100 billion industry by 2025. 


On the other hand, the Middle East & Africa owns the least share of the global Gitelman syndrome market due to the presence of poor economies, especially in the Africa region. Moreover, stringent government policies hinder the market growth within the region. The Middle East holds a major share of the market due to the well-developed healthcare sector and the presence of developed economies within the region. 


Research Methodology


Gitelman Syndrome Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


 


Key players in global Gitelman syndrome market


Some of the key players in the global Gitelman syndrome market are Pfizer Inc. (U.S.), Hisoar (China), Taj Pharmaceuticals Ltd. (India), Merck & Co., Inc. (U.S.), Xinhua Pharm (China), BIOCAUSE Inc. (China), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), Abbott (U.S.), Danaher (U.S.), Agilent Technologies (U.S.), and others.


 



Frequently Asked Questions (FAQ) :


Increasing cases of chronic kidney diseases is the major driver of the global Gitelman syndrome market.

Limited availability of treatments and lack of awareness of the diseases can restrain the global Gitelman syndrome market growth.

Gitelman syndrome market is expected to exhibit a CAGR of 7.6% from 2018 to 2023.

The Americas can dominate the global Gitelman syndrome market till 2023.

QIAGEN, Agilent Technologies, Bio-Rad Laboratories, Inc., Danaher, Taj Pharmaceuticals Ltd., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., BIOCAUSE Inc., Abbott, Xinhua Pharm, Pfizer Inc., Hisoar, and others are major players of the global Gitelman syndrome market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Gitelman Syndrome Market, by Diagnosis

6.1 Introduction

6.2 Urine Electrolytes Tests

Market Estimates & Forecast, 2020-2027

6.2.1 Sodium Test

6.2.2 Potassium Test

6.2.3 Chloride Test

6.2.4 Others

6.3 Molecular Genetic Tests

Market Estimates & Forecast, 2020-2027

6.3.1 PCR (Polymerase Chain Reaction)

6.3.2 Hybridization

6.3.3 Others

6.4 Others

Chapter 7. Global Gitelman Syndrome Market, by Treatment

7.1 Introduction

7.2 Supplements

Market Estimates & Forecast, 2020-2027

7.2.1 Potassium Supplement

7.2.2 Magnesium Supplement

7.2.3 Others

7.3 Medication

Market Estimates & Forecast, 2020-2027

7.3.1 Diuretics

Market Estimates & Forecast, 2020-2027

7.3.1.1 Spironolactone

7.3.1.2 Amiloride

7.3.1.3 Others

7.3.2 Anti-Inflammatory Drugs (NSAIDS)

Market Estimates & Forecast, 2020-2027

7.3.2.1 Ibuprofen

7.3.2.2 Indomethacin

7.3.2.3 Others

7.4 Others

Chapter 8 Global Gitelman Syndrome Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, 2020-2027

8.3 Diagnostic Labs

Market Estimates & Forecast, 2020-2027

8.4 Research Organization

Market Estimates & Forecast, 2020-2027

8.5 Others

Chapter 9. Global Gitelman Syndrome Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Pfizer Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Hisoar

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Taj Pharmaceuticals Ltd.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Merck & Co., Inc.

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Xinhua Pharm

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 BIOCAUSE Inc.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Thermo Fisher Scientific Inc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Bio-Rad Laboratories, Inc.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 F. Hoffmann-La Roche Ltd

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 QIAGEN

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Abbott

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Danaher

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Agilent Technologies

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Gitelman Syndrome Industry Synopsis, 2020-2027

Table 2 Global Gitelman Syndrome Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Gitelman Syndrome Market by Region, 2020-2027, (USD Million)

Table 4 Global Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 6 Global Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 7 North America Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 10 U.S. Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 11 U.S. Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 12 U.S. Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 13 Canada Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 16 South America Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 19 Europe Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 22 Western Europe Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 25 Eastern Europe Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 28 Asia Pacific Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

Table 31 Middle East & Africa Gitelman Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa Gitelman Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Gitelman Syndrome Market by End User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Gitelman Syndrome Market

Figure 3 Market Dynamics for Global Gitelman Syndrome Market

Figure 4 Global Gitelman Syndrome Market Share, by Diagnosis 2020

Figure 5 Global Gitelman Syndrome Market Share, by Treatment 2020

Figure 6 Global Gitelman Syndrome Market Share, by End User, 2020

Figure 7 Global Gitelman Syndrome Market Share, by Region, 2020

Figure 8 North America Gitelman Syndrome Market Share, by Country, 2020

Figure 9 Europe Gitelman Syndrome Market Share, by Country, 2020

Figure 10 Asia Pacific Gitelman Syndrome Market Share, by Country, 2020

Figure 11 Middle East & Africa Gitelman Syndrome Market Share, by Country, 2020

Figure 12 Global Gitelman Syndrome Market: Company Share Analysis, 2020 (%)

Figure 13 Pfizer Inc.: Key Financials

Figure 14 Pfizer Inc.: Segmental Revenue

Figure 15 Pfizer Inc.: Geographical Revenue

Figure 16 Hisoar: Key Financials

Figure 17 Hisoar: Segmental Revenue

Figure 18 Hisoar: Geographical Revenue

Figure 19 Taj Pharmaceuticals Ltd.: Key Financials

Figure 20 Taj Pharmaceuticals Ltd.: Segmental Revenue

Figure 21 Taj Pharmaceuticals Ltd.: Geographical Revenue

Figure 22 Merck & Co., Inc.: Key Financials

Figure 23 Merck & Co., Inc.: Segmental Revenue

Figure 24 Merck & Co., Inc.: Geographical Revenue

Figure 25 Xinhua Pharm: Key Financials

Figure 26 Xinhua Pharm: Segmental Revenue

Figure 27 Xinhua Pharm: Geographical Revenue

Figure 28 BIOCAUSE Inc.: Key Financials

Figure 29 BIOCAUSE Inc.: Segmental Revenue

Figure 30 BIOCAUSE Inc.: Geographical Revenue

Figure 31 Thermo Fisher Scientific Inc.: Key Financials

Figure 32 Thermo Fisher Scientific Inc.: Segmental Revenue

Figure 33 Thermo Fisher Scientific Inc.: Geographical Revenue

Figure 34 Bio-Rad Laboratories, Inc.: Key Financials

Figure 35 Bio-Rad Laboratories, Inc.: Segmental Revenue

Figure 36 Bio-Rad Laboratories, Inc.: Geographical Revenue

Figure 37 F. Hoffmann-La Roche Ltd: Key Financials

Figure 38 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 39 F. Hoffmann-La Roche Ltd.: Geographical Revenue

Figure 40 QIAGEN: Key Financials

Figure 41 QIAGEN: Segmental Revenue

Figure 42 QIAGEN: Geographical Revenue

Figure 43 Abbott: Key Financials

Figure 44 Abbott: Segmental Revenue

Figure 45 Abbott: Geographical Revenue

Figure 46 Danaher: Key Financials

Figure 47 Danaher: Segmental Revenue

Figure 48 Danaher: Geographical Revenue

Figure 49 Agilent Technologies: Key Financials

Figure 50 Agilent Technologies: Segmental Revenue

Figure 51 Agilent Technologies: Geographical Revenue